LEVOFLOXACIN ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H20FN3O4
Molecular Weight	361.3675
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4

InChI

InChIKey=GSDSWSVVBLHKDQ-JTQLQIEISA-N

InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf

Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV 62 Target ID: CHEMBL2363033 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26525786	Inhibitor 8297
DNA gyrase 26 Target ID: CHEMBL2311225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26459538	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Pneumonia 90 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8429	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Complicated Skin and Skin Structure Infections 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8429	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Chronic bacterial prostatitis 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8429	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Plague 14 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8429	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Chronic bronchitis 51 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8429	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996
Urinary tract infections 205 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8429	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 1996

C_max

Value	Dose	Analyte	Population
7.9 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.8 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
11.8 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.85 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
2.04 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.3 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
49.6 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
59 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
118 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
111 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
19.88 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
55.3 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
7.6 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.9 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.9 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
5.97 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.6 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.2%) Nausea (0.6%) Vomiting (0.5%) Dizziness (0.3%) Headache (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 substrate 1737	inhibitor 1767 substrate 1037	inhibitor 1852 substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 OCTN2 66	CYP1A2 1054 CYP2C19 991 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A10 291 OATP1A2 62 OATP2B1 104 OATP1B1 406 OATP1B3 350 P-gp 1537 BCRP 561

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	inconclusive	levofloxacin-N-oxide 6
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: -	no
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2B6 1001	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	weak	levofloxacin-N-oxide 6
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: -	yes [IC50 210 uM]
OCTN2 71	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16928358/ Page: -	yes [IC50 6800 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	yes	levofloxacin-N-oxide 6
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	yes	levofloxacin-N-oxide 6

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
OATP1B1 406	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
OATP1B3 350	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
OATP2B1 104	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
UGT1A10 291	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A6 307	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A8 283	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
OATP1A2 62	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	yes [Km 136 uM]
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17978494/ Page: -	yes
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17978494/ Page: -	yes
UGT1A1 418	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes
UGT1A3 422	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes
UGT1A7 236	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/16474415/ Page: -

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-6360	http://www.3bsc.com/index/pro_info.php?id=122847
3B Scientific (Wuhan) Corp	3B1-01436	http://www.3bsc.com/index/pro_info.php?id=21648
AA Blocks	AA0003AY	http://www.aablocks.com/goods/Goods/detail?id=AA0003AY
AEchem Scientific Corp., USA	AE020182	http://www.aechemsc.com/info_products/AE020182.php
Aaron Chemicals	AR00042Q	http://www.aaronchem.com/100986-85-4
Achemtek	0104-018860	http://www.achemtek.com/100986-85-4
Achemtek	0104-011027	http://www.achemtek.com/138199-71-0
Acorn PharmaTech	ACN-038325	http://www.acornpharmatech.com/
Alsachim	853	http://www.alsachim.com/product-C2615-glo.bal-view.html
Ambinter	Amb20669810	http://www.ambinter.com/reference/20669810
Ambinter	Amb2444040	http://www.ambinter.com/reference/2444040
ApexBio Technology	B1959	http://www.apexbt.com/levofloxacin.html
ApexBio Technology	A5511	http://www.apexbt.com/ofloxacin.html
Aurora Fine Chemicals LLC	A17.890.330	http://online.aurorafinechemicals.com/info?ID=A17.890.330
BLD Pharm	BD0022	http://www.bldpharm.com/products/100986-85-4.html
BioSynth	Q-201295	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/Q-201295.html
CSNpharm	CSN10001	https://www.csnpharm.com/products/levofloxacin.html
Chem Scene	CS-2218	http://www.chemscene.com/100986-85-4.html
ChemMol	30101095	http://www.chemmol.com/chemmol/30101095.html
ChemMol	49401467	http://www.chemmol.com/chemmol/49401467.html
Chemenu	CM110290	http://www.chemenu.com/products/CM110290
Chemspace	CSSB00016993440	https://chem-space.com/CSSB00016993440
Clearsynth	CS-O-01741	http://www.clearsynth.com/en/CSO01741.html
DC Chemicals	DCAPI1002	http://www.dcchemicals.com//product_show-Levofloxacin_Levaquin_.html
Excenen	EX-A1488	http://www.excenen.com/searchresultlist.php?id=100986-85-4
Hairui	HR127302	http://www.hairuichem.com/en/product/100986-85-4.html
LGC Standards	DRE-C14629730	https://www.lgcstandards.com/US/en/p/DRE-C14629730
LGC Standards	LGCFOR0846.00	https://www.lgcstandards.com/US/en/p/LGCFOR0846.00
LGC Standards	MM0846.00	https://www.lgcstandards.com/US/en/p/MM0846.00
Lab Network	LN00235793	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00235793
MedChem Express	HY-B0330	https://www.medchemexpress.com/Levofloxacin.html
MuseChem	I000113	https://www.musechem.com/product/I000113.html
OChem	3793	http://www.ocheminc.com/index.php?act=psearch&pid=986L854
Otava	12488923	https://search.otavachemicals.com/#!/search?query=12488923&type=code&base=dbb
Sigma-Aldrich	L-038_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/l038?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	40922_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/40922?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	28266_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/28266?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S061060	http://www.sinfoobiotech.com/product/1064463
Smolecule	S532946	http://www.smolecule.com/products/s532946
TCI (Tokyo Chemical Industry)	L0193	http://www.tcichemicals.com/eshop/en/us/commodity/L0193/index.html
THE BioTek	bt-273347	https://www.thebiotek.com/product/inhibitors/bt-273347
VladaChem	VL261985-25G	https://www.vladachem.com/product.php?products=100986-85-4
Yuhao Chemical	LT1250	http://www.chemyuhao.com/100986-85-4.html
abcr GmbH	AB250203	http://www.abcr.com/shop/en/AB250203
eNovation Chemicals	D674497	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674497
eNovation Chemicals	Y1040229	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1040229
iChemical	EBD8264	http://www.ichemical.com/products/100986-85-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-2011834955	https://mcule.com/MCULE-2011834955/

PubMed

Title	Date	PubMed
In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.	2001	11447768
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.	2001	11347723
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.	2001	11327197
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.	2001 Apr	11404068
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).	2001 Apr	11404067
In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.	2001 Apr	11399019
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].	2001 Apr	11398326
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion.	2001 Apr	11379965
In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.	2001 Apr	11322420
[Use of levofloxacine in primary care for outbreaks in COPD].	2001 Apr 15	11334579
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.	2001 Aug 15	11462189
Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.	2001 Feb	11396281
Quinolones alter defense reactions mediated by macrophages.	2001 Feb	11360919
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells.	2001 Jan	11349764
[Levofloxacin adverse effects, data from clinical trials and pharmacovigilance].	2001 Jan-Feb	11322015
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.	2001 Jul	11463526
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.	2001 Jul	11463525
New directions in antiinfective therapy for community-acquired pneumonia in the emergency department.	2001 Jul	11446525
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.	2001 Jul	11446524
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.	2001 Jul	11446523
The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.	2001 Jul	11446520
Levofloxacin and warfarin interaction.	2001 Jul	11444586
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.	2001 Jul	11418525
Activity of levofloxacin and ciprofloxacin against urinary pathogens.	2001 Jul	11418511
Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?	2001 Jul-Aug	11399859
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.	2001 Jun	11455504
Complicated urinary tract infections in patients with voiding dysfunction.	2001 Jun	11442992
Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy.	2001 Jun	11408986
Levofloxacin failure in a patient with pneumococcal pneumonia.	2001 Jun	11408985
Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece.	2001 Jun	11397616
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.	2001 Jun	11397615
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.	2001 Jun	11389122
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.	2001 Jun	11389113
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.	2001 Mar	11406752
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.	2001 Mar	11337189
Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice.	2001 Mar	11325396
Treatment of tularemia with levofloxacin.	2001 Mar	11318818
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.	2001 Mar	11318077
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.	2001 May	11388112
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.	2001 May	11370709
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.	2001 May	11337224
Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery.	2001 May	11328803
Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.	2001 May	11328784
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.	2001 May	11328779
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.	2001 May	11328772
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.	2001 May 15	11317266
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.	2001 May-Jun	11448565
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.	2001 May-Jun	11448564
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.	2001 May-Jun	11448563
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.	2001 May-Jun	11448561

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours. Nosocomial Pneumonia: 750 mg during 7–14 days Community Acquired Pneumonia: 500 mg during 7–14 days Community Acquired Pneumonia§ 750 mg during 5 days Complicated Skin and Skin Structure Infections (SSSI) 750 mg during 7–14 days Uncomplicated SSSI 500 mg during 7–10 days Chronic Bacterial Prostatitis 500 mg during 28 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 750 mg during 5 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 250 mg during 10 days Uncomplicated Urinary Tract Infection 250 mg 3 during days Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg during 7 days Acute Bacterial Sinusitis (ABS) 750 mg days or 500 mg during 10–14 days.

Route of Administration: Other

In Vitro Use Guide

Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.

Name

Type

Language

LEVOFLOXACIN ANHYDROUS

Common Name

English

OFLOXACIN S-(-)-FORM [MI]

Common Name

English

OFLOXACIN S-(-)-FORM

Common Name

English

Levofloxacin [WHO-DD]

Common Name

English

NSC-758709

Code

English

levofloxacin [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

J01MA12